Common Contracts
1 similar Shared Care Guideline contracts
Shared Care GuidelineShared Care Guideline • May 28th, 2013
Denosumab Treatment of osteoporosis in post menopausal women Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing the prescribing of denosumab for indications listed below. Indication NICE guidance recommends denosumab as a treatment option for the primary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures:• who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and• who have a combination of T-score, age and number of independent clinical risk factors for fracture as indicated in the following table. Denosumab is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instruction
